RGEN vs. ALNY, BIIB, UTHR, NBIX, INCY, BMRN, EXAS, EXEL, HALO, and MDGL
Should you be buying Repligen stock or one of its competitors? The main competitors of Repligen include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), Exelixis (EXEL), Halozyme Therapeutics (HALO), and Madrigal Pharmaceuticals (MDGL). These companies are all part of the "biotechnology" industry.
Repligen vs.
Repligen (NASDAQ:RGEN) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability, community ranking, media sentiment and analyst recommendations.
Repligen presently has a consensus price target of $185.20, indicating a potential upside of 15.38%. Alnylam Pharmaceuticals has a consensus price target of $298.61, indicating a potential upside of 21.25%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Alnylam Pharmaceuticals is more favorable than Repligen.
In the previous week, Alnylam Pharmaceuticals had 26 more articles in the media than Repligen. MarketBeat recorded 29 mentions for Alnylam Pharmaceuticals and 3 mentions for Repligen. Repligen's average media sentiment score of 0.80 beat Alnylam Pharmaceuticals' score of 0.70 indicating that Repligen is being referred to more favorably in the media.
Repligen has higher earnings, but lower revenue than Alnylam Pharmaceuticals. Repligen is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Repligen has a net margin of -3.36% compared to Alnylam Pharmaceuticals' net margin of -15.86%. Repligen's return on equity of 3.90% beat Alnylam Pharmaceuticals' return on equity.
97.6% of Repligen shares are held by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. 1.2% of Repligen shares are held by company insiders. Comparatively, 1.5% of Alnylam Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Repligen has a beta of 0.97, meaning that its stock price is 3% less volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals has a beta of 0.34, meaning that its stock price is 66% less volatile than the S&P 500.
Alnylam Pharmaceuticals received 729 more outperform votes than Repligen when rated by MarketBeat users. Likewise, 76.17% of users gave Alnylam Pharmaceuticals an outperform vote while only 67.49% of users gave Repligen an outperform vote.
Summary
Alnylam Pharmaceuticals beats Repligen on 10 of the 18 factors compared between the two stocks.
Get Repligen News Delivered to You Automatically
Sign up to receive the latest news and ratings for RGEN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Repligen Competitors List
Related Companies and Tools
This page (NASDAQ:RGEN) was last updated on 1/20/2025 by MarketBeat.com Staff
Free RGEN Stock Alerts